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Intestinal organoids are an excellent model to study epithelial biology. Yet, the selection of
analytical tools to accurately quantify heterogeneous organoid cultures remains limited.
Here, we developed a semi-automated organoid screening method, which we applied
to a library of highly specific chemical probes to identify epigenetic regulators of intestinal
epithelial biology. The role of epigenetic modifiers in adult stem cell systems, such
as the intestinal epithelium, is still undefined. Based on this resource dataset, we
identified several targets that affected epithelial cell differentiation, including HDACs,
EP300/CREBBP, LSD1, and type I PRMTs, which were verified by complementary
methods. For example, we show that inhibiting type I PRMTs, which leads enhanced
epithelial differentiation, blocks the growth of adenoma but not normal organoid cultures.
Thus, epigenetic probes are powerful tools to study intestinal epithelial biology and may
have therapeutic potential.
Keywords: organoids, epigenetic modifiers, intestinal stem cell biology, bioimage analysis, PRMT1, EP300,
CREBBP
INTRODUCTION
The intestinal epithelium, a single layer of cells, faces the challenge of both providing a barrier
against pathogens while also being responsible for the uptake of nutrients and water. One of
the hallmarks of intestinal epithelium is the rapid turnover of 3–5 days, which is driven by
LGR5+ intestinal stem cells (ISCs) that reside at the bottom of crypts. ISCs are continuously
dividing and give rise to progenitor cells, which differentiate into specialized intestinal epithelial
cell (IEC) lineages such as absorptive enterocytes and secretory lineages such as mucus-producing
goblet cells, antimicrobial-producing Paneth cells, hormone-secreting enteroendocrine cells, and
chemosensory tuft cells (Gehart and Clevers, 2019). The intestinal epithelium exhibits high
plasticity in respond to challenges (Haber et al., 2017; Jadhav et al., 2017). On the other hand, it is
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vulnerable to tumorigenesis with colorectal cancer being the
second leading cause of cancer-related deaths worldwide.
The balance between ISC proliferation and IEC differentiation
is controlled by pathways including WNT, BMP, and NOTCH
(Gehart and Clevers, 2019). Specific transcription factors, such
as ATOH1, are critically required for acquisition of IEC effector
lineage identities (Yang et al., 2001). Gene expression is further
determined by the chromatin landscape. It is known that
epigenetic marks such as methylated DNA and histone tail
modifications differ strongly between fetal and adult intestine
(Kazakevych et al., 2017; Jadhav et al., 2019), and can be altered
in intestinal pathologies (Ray and Longworth, 2019). While the
requirement of epigenetic modifications for embryonic stem cell
differentiation (Atlasi and Stunnenberg, 2017) and differentiation
and maturation of immune cells (Álvarez-Errico et al., 2015)
has been extensively studied, their role for maintenance of
intestinal homeostasis is debated. Both a permissive chromatin
structure and regulation of IEC lineage differentiation by
transcription factors, and a control of gene expression patterns
by the chromatin states itself have been proposed as conflicting
models (extensively reviewed by Elliott and Kaestner, 2015). The
classic NOTCH-mediated lateral inhibition model of ISC-to-
IEC differentiation has been attributed to a broadly permissive
chromatin landscape, supporting the idea of regulation by
transcription factors as the most defining factor (Kim et al.,
2014). However, other studies suggest that ISC differentiation
and the de-differentiation of lineage-defined IECs back to ISCs
are mediated by changes in DNA methylation and chromatin
accessibility (Kaaij et al., 2013; Sheaffer et al., 2014; Jadhav
et al., 2017; Kazakevych et al., 2017). Several hundred epigenetic
modification enzymes contribute to writing, erasing, and reading
the epigenetic code (Arrowsmith et al., 2012). Currently, the
investigation of the role of epigenetic modifiers in the intestinal
epithelium depends mostly on labor-intensive mouse models
with conditional genetic deletion, allowing for the examination
of one or few epigenetic modifiers at the same time (Gonneaud
et al., 2016b; Koppens et al., 2016). A higher throughput could
be achieved by using organoids to investigate epigenetic effects in
the intestinal epithelium (Kraiczy and Zilbauer, 2019). Curated
by the Structural Genomics Consortium, an openly accessible
chemical probe library targeting epigeneticmodification enzymes
with high selectivity and specificity became available recently
(Ackloo et al., 2017; Scheer et al., 2019). Treating organoids with
this chemical probe library will enable a direct comparison of the
putative requirement of many epigenetic modifiers for epithelial
homeostasis or differentiation of IEC lineages.
Heterogeneous organoid cultures are quite sensitive to
subtle changes in handling and culture conditions. Therefore,
development of quantitative analysis methods for reproducible
quantification of a whole organoid population instead of relying
on representative example data points is crucial (Huch et al.,
2017). Indeed, this has recently led to specialized studies such
as using light-sheet microscopy to elegantly define symmetry
breaking (Serra et al., 2019), using single-cell RNA sequencing
(scRNA-seq) to describe epithelial responses to immune cues
(Haber et al., 2017; Biton et al., 2018), or analysis of single
intestinal organoids in microcavity arrays (Brandenberg et al.,
2020). However, these techniques are costly and the required
instrumentation and data analysis pipelines are not widely
available to the research community. Thus, quantitative but cost-
efficient tools based on standard laboratory equipment that can
be scaled to screen setups need to be established.
Here, we provide a semi-automated organoid quantification
method suitable for screening experiments and designed to
be used in laboratories with a standard infrastructure. To
widely investigate the role of epigenetic modifiers for adult
intestinal epithelial homeostasis, we combined this toolbox
with a chemical probe library consisting of 39 inhibitors that
target epigenetic modification enzymes with high selectivity and
specificity (Scheer et al., 2019). From this screen dataset, we
identified several mediators of IEC biology that we verified with
complementary methods. We envision that this resource will be
useful for the research community and will lay basis for further
mechanistic investigation. Specifically, we find new regulators of
organoid size related to ISC frequency, as well as new regulators
of IEC differentiation. Finally, we explore the potential of some
of these probes for treatment of intestinal cancer by application
on intestinal tumor organoids.
RESULTS
Development of a Toolbox to Quantify
Intestinal Organoid Growth and Cellular
Composition
A decade after its establishment by Sato et al. (2009), the
use of intestinal organoids has been become a standard
in the method repertoire. However, accurately quantifying
heterogeneous organoid cultures remains a challenge and the
analytical tools available to a broad community, especially for
screening purposes, remain limited or labor intensive. We
thus initiated a small intestinal (SI) organoid system that,
similar to the original work, starts with freshly isolated crypts
that self-organize into budding organoids by day 4 (96 h
after seeding), which can be split and propagated (Figure 1A,
Supplementary Figure 1a). We next designed a setup to daily
acquire bright-field z-stack images of the whole extracellular
matrix (Matrigel droplet) in a well, followed by automatic
segmentation and quantification of all individual organoids based
on the open-source tools ImageJ/Fiji and Ilastik (Figure 1B).
Based on edge detection in each stack layer, this workflow can
be used to robustly quantify organoid size (object area) and
classify, e.g., by determining intensity, organoid phenotypes over
time (Figure 1C, Supplementary Figures 1b,c). The workflow is
robust to changes in morphology, stitching artifacts, and can be
adjusted to image data from different automated microscopes.
As the object classification by Ilastik is not dependent on deep
learning and extensive training data, it can easily be adapted to
new phenotypes and changes in experimental conditions.
In addition to determining organoid size, the cellular
composition is of critical interest. We therefore selected
transcripts that are specific for individual IEC lineages (Haber
et al., 2017), and performed qRT-PCR on these within a
24–96 h time course (Figure 1D). Except for the enterocyte
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FIGURE 1 | Quantification of intestinal organoid growth and cellular composition. (A) Scheme of organoid formation and images of a representative position 24–96 h
after seeding. Whole well is shown in Supplementary Figure 1a. (B) Scheme of organoid size quantification workflow using open-source tools ImageJ/Fiji and Ilastik.
Visual quantification output and ImageJ quantification results are shown in Supplementary Figures 1b,c. (C) Box plots showing organoid size quantified as object
area at 24–96 h timepoints (top). Object area vs. object mean gray value (8-bit scale) on a minimum projection of the image stack (bottom). Pooled data from 2 biol.
replicates, indicated by shape. Each dot represents one organoid. (D) mRNA expression of IEC lineage marker genes at 24–96 h timepoints, measured by qRT-PCR.
xfold change relative to 96 h organoids, median of 3 biol. replicates. (E) Flow cytometry of organoids grown for 48 and 96 h. Staining of representative replicate
(bottom right). Population frequencies in Cells parent gate, 3 biol. replicates, indicated by shape. Mean highlighted (bottom left). Log2 fold change relative to 96 h
timepoint, median of 3 biol. replicates. Dot size corresponds to absolute log2 fold change (top left). Gating strategy and population frequencies for FSC_CD326hi and
FSC_CD24+ parent gates are shown in Supplementary Figures 1d,e. (F) Organoids cultured for 48 h followed by 72 h (48 h_72 h) with normal culture medium
(ENR_ENR), or culture medium containing CHIR+VPA_CHIR+VPA, CHIR+VPA_CHIR+DAPT, or CHIR+VPA_IWP2+DAPT to modify IEC composition by interfering with
Wnt and Notch signaling pathways as indicated, adapted from Yin et al. (2014). mRNA expression measured by qRT-PCR. xfold change relative to ENR_ENR
treatment. 3 biol. replicates, indicated by shape. Mean highlighted. (G) Flow cytometry of organoids treated for 48_72h as indicated, population frequencies
normalized to ENR_ENR treatment. Log2 fold change, median of 3 biol. replicates. Dot size corresponds to absolute log2 fold change. Gating strategy, representative
staining and population frequencies for FSC_CD326hi and FSC_CD24+ parent gates are shown in Supplementary Figures 1d,f–h.
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marker Alpi, we generally find an increase in lineage-specific
gene expression over time cumulating at 96 h (Figure 1D).
This corresponds to the transition from spheroids, consisting
mainly of progenitors, to mature budding organoids that
contain more differentiated lineages, as was shown previously
(Serra et al., 2019). As a complementary technique to quantify
cellular composition on a single-cell level, we conducted flow
cytometry of commonly used IEC surface markers (Figure 1E,
Supplementary Figures 1d,e). The differences between 48 and
96 h organoids were modest (Figure 1E). Of note, we observed
that the frequency ofUlex europaeus agglutinin 1 (UEA1) positive
cells reduced over time, indicating that the population expressing
UEA1 on the surface may be progenitor cells that are different
from the population of UEA1bright secretory cells commonly
detected by immunofluorescence staining of permeabilized tissue
(Figure 1E). As a proof of principle, we next tested our approach
on organoids with an altered cell composition. Interfering with
WNT and NOTCH signaling pathways has previously been
established by Yin and colleagues as amethod to enrich organoids
for stem cells, Paneth cells, goblet cells, or enteroendocrine cells
(Yin et al., 2014). WNT and NOTCH pathways are activated
or respectively inhibited by treatment with combinations of
the glycogen synthase kinase 3 (GSK3) inhibitor CHIR99021
(CHIR), valproic acid (VPA), the porcupine inhibitor IWP2,
or the gamma-secretase inhibitor DAPT (Yin et al., 2014)
(Figure 1F). Interestingly, we found that incubation with CHIR
+ VPA followed by IWP2 + DAPT increased the expression of
tuft cell marker genes in addition to the previously described
effects on goblet cells and enteroendocrine cells (Figure 1F).
Drastic effects on the cell composition were reflected by
widely altered surface marker expression measured by flow
cytometry and resulted in characteristic patterns (Figure 1G,
Supplementary Figures 1d,f,g). However, we observed that well
established flow cytometry gating strategies, such as identifying
Paneth cells by a SSChi_CD24+ gate (Sato et al., 2011),
did not follow the Lyz1 gene expression pattern in some
conditions (Figure 1F, Supplementary Figure 1h). Thus, while
flow cytometry demonstrates to be very useful to detect
changes in the organoid composition, surface marker expression
may be influenced by additional factors, such as the growth
conditions, and identification of certain cell populations by
flow cytometry requires appropriate controls. In summary, we
developed an easy-to-use and cost-efficient toolbox for the
analysis of (intestinal) organoids that is suitable to detect changes
in organoid growth and cell composition.
Organoid Screen of Epigenetic Modifier
Inhibitors Identifies Established Drugs
Targeting Cancer Growth
Next, we applied our organoid toolbox for screening of a
chemical probe library that targets epigenetic modifiers to
modulate the epigenome (Scheer et al., 2019). Organoids
generated from 4 individual mice were grown in the presence
of 39 inhibitors, with DMSO vehicle and VPA serving as
controls (Figures 2A,B). Samples were imaged daily and
expression of 12 transcripts specific for IEC lineages (Haber
et al., 2017) was analyzed at the 96 h endpoint (Figure 2A).
We observed that some of the probes significantly affected
organoid growth as determined by area (Figures 2C,D,
Supplementary Figures 2a–c, 3A). Integration of the primary
readouts revealed a strong correlation of organoid size and
expression of the ISC marker gene Lgr5 (Figure 2E). We found
three probes that reduced both organoid size and Lgr5 mRNA
expression, namely the pan-Poly (ADP-ribose) polymerase
(PARP) inhibitor olaparib and two histone deacetylase (HDAC)
inhibitors LAQ824 (Dacinostat), a pan-HDAC inhibitor, and
CI-994 (Tacedinaline), an HDAC1-3 and HDAC8 inhibitor
(Figures 2C–E, Supplementary Figures 2b,c) (Weisberg et al.,
2004; Beckers et al., 2007; Mateo et al., 2019). These findings are
in agreement with a study that showed reduced growth and Lgr5
gene expression but a gain of enterocyte marker expression in
CI-994 treated organoids (Gonneaud et al., 2016a). Olaparib-
treated organoids would sufficiently grow to perform flow
cytometry. This allowed us to use Lgr5-EGFP expressing reporter
organoids to confirm the reduced Lgr5 gene expression levels.
Indeed, we found markedly fewer GFP-high/GFP-positive cells
in olaparib-treated compared to control organoids (Figure 2F,
Supplementary Figure 2d). Finally, we treated Adenomatous
polyposis coli (Apc) knockout organoids, which are a model for
intestinal cancer, with the two HDAC inhibitors and olaparib
and found that these probes also limited growth in these tumor
cultures, with similar growth reductions compared to WT
organoids (Figure 2G). Together, this is well in line with the
design goal of these probes to limit cellular growth to target
cancer cells.
Inhibition of EP300/CREBBP Enhances
Organoid Size and Lgr5 Expression
We next focused on probes that increased organoid
size (Figures 2B–D). We found that both SGC-CBP30
and I-CBP112 significantly increased the organoid area
(Supplementary Figure 3a) and this increase was seen in
objects that were classified as “Organoids” and thus was not
dependent on the occurrence of large spheres (Figure 3A,
Supplementary Figure 3b). In support of the sensitivity of our
assay, both probes have the same targets: EP300/CREBBP. E1A
Binding Protein P300 (EP300, P300) and Creb-binding protein
(CREBBP, CBP) are closely related bromodomain-containing
acetyltransferases that serve as transcriptional co-activators for
numerous transcription factors (Goodman and Smolik, 2000;
Ramos et al., 2010; Raisner et al., 2018). Both SCG-CBP30
and I-CBP112 specifically target the bromodomain-binding
domain, which thus renders these proteins unable to bind
acetylated lysines. The observed increase in organoid size was
surprising since both inhibitors have been designed to cause
growth restriction in cancer cells (Hay et al., 2014; Picaud et al.,
2015; Attar and Kurdistani, 2017). Comparing SGC-CBP30/I-
CBP112-treated organoids with the DMSO vehicle control,
organoid morphology appeared normal, however, we observed
a reduction of putative goblet/Paneth cells as determined by
cytosolic UEA1 staining (Figure 3B, Supplementary Figure 3c).
We next tested whether these probes would expand the LGR5+
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FIGURE 2 | Organoid screen of epigenetics probes identifies established cancer drugs. (A) Scheme of screen setup and follow-up experiments. (B) Inhibitors used in
screen, detailed information is provided in Supplementary Table 1. Probes used in follow-up experiments are highlighted. Abbreviations of inhibitor target families
(inhibitor class): BRD, bromodomain; BET, bromodomain and extra-terminal motif; HAT, histone acetyltransferase; KDM, lysine demethylase; PMT, protein
methyltransferase; KMT, lysine methyltransferase; PRMT, protein arginine methyltransferase; MBT, malignant brain tumor; HDAC, histone deacetylase. (C) Median
object area of organoids treated with DMSO or inhibitors for 0–96 h. Median of 4 biol. replicates. Boxplots for each inhibitor and timepoint are shown in
Supplementary Figure 2a. Probes that altered organoid size and were followed-up are highlighted: Controls, CI-994, LAQ824 (HDAC inhibitors), olaparib (PARP
inhibitor), SGC-CBP30, I-CBP112 (BRD_BET inhibitors). (D) Representative replicates, 96 h timepoint. (E) Correlation of median organoid size and relative Lgr5 gene
expression, median of 4 biol. replicates. Pearson coefficient. (F) Frequency of Lgr5-EGFP stem cells in reporter organoids treated with DMSO or olaparib for 96 h.
Gating of representative replicate (top) and percentage of GFPhi cells, normalized to DMSO control. 5 biol. replicates, indicated by shape. Mean highlighted. Minimum
5,000 viable cells in parent gate. Paired t-test (bottom). Percentage of total GFP+ cells is shown in Supplementary Figure 2d. (G) Apc-deficient adenomas treated
with DMSO, CI-994, LAQ824, or olaparib for 96 h. Representative replicate (top) and quantification of object size in 7/3/3/7 (DMSO/CI-994/LAQ828/olaparib)
individual wells (bottom).
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FIGURE 3 | Inhibition of EP300/CREBBP enhances organoid size and Lgr5 expression. (A) Organoids treated with DMSO, SCG-CBP30, or I-CBP112 for 96 h. Area
of objects classified as “Organoid” by combined ImageJ/Ilastik workflow. 4 biol. replicates, indicated by shape. (B) Representative organoids treated with DMSO,
SCG-CBP30, or I-CBP112 for 96 h. 10x magnification, max. intensity projection. KI67 staining marks crypt regions (top). Density of UEA1+ cells, each value
represents the median of ≥5 organoids quantified. 3/2/3 biol. replicates, indicated by shape. Mean highlighted (bottom). Full wells for one representative replicate is
shown in Supplementary Figure 3c. (C) Frequency of Lgr5-EGFP stem cells in reporter organoids grown in ENR or ENR+CHIR and treated with DMSO,
SCG-CBP30, or I-CBP112 for 96 h, measured by flow cytometry. Gating of representative replicate grown in ENR (top) and percentage of GFPhi cells normalized to
ENR DMSO condition of 3 biol. replicates, indicated by shape. Mean highlighted. Paired t-test (bottom). Percentage of total GFP+ cells is shown in
Supplementary Figure 3d. (D) Volcano plot of mRNA sequencing of untreated vs. I-CBP112 treated organoids, 4 biol replicates per group. Selected genes are
highlighted. (E) mRNA sequencing of untreated vs. I-CBP112 treated organoids. GSEA of LGR5+ stem cell signature from Muñoz et al. (2012) (GSE33949).
Normalized enrichment score (NES) and false discovery rate (FDR) are indicated.
cell population in Lgr5-EGFP organoids and found a modest
increase upon treatment, either alone or in combination with our
positive control CHIR, an activator of canonical WNT signaling
(Figure 3C, Supplementary Figures 3d,e). However, incubation
with SGC-CBP30 or I-CBP112 could not enhance organoid
growth under low EGF concentrations, replace R-Spondin in
the culture medium, or overcome treatment with the WNT
inhibitor IWP2 (Supplementary Figures 3f,g). To determine
which genes are under the control of EP300/CREBBP in the
intestinal epithelium, we performed mRNA sequencing on
untreated vs. I-CBP112 treated organoid cultures. In accordance
with a transcriptional co-activator role for EP300/CREBBP,
we found 53 genes upregulated and 110 genes downregulated
using a log2 fold change cutoff of 0.5 and padjust ≤ 0.01
(Figure 3D). Furthermore, signatures of transcription factors
known to interact with either EP300 or CREBBP were negatively
enriched (Supplementary Figure 3h). Remarkably, Lgr5
was the most significantly upregulated gene in our dataset,
substantiating our previous results (Figure 3D). In support,
gene set enrichment analysis (GSEA) with a LGR5+ stem
cell gene set (Muñoz et al., 2012) showed positive correlation
(Figure 3E). The second most significantly upregulated gene
was Egr1 (Figure 3D), which is an inducible transcription factor
that is involved in cell proliferation (Gitenay and Baron, 2009).
The expansion of ISCs or progenitors appears to come at a
cost to the differentiation of other cell lineages. We observed
reduced UEA1 staining and downregulation of goblet cell
markers such as Muc4 and Ccl6 following EP300/CREBBP
inhibition (Figures 3B,D). This is further supported by the
negative correlation with secretory cell gene sets by GSEA
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(Supplementary Figure 3i). Conversely, this is in line with
positive enrichment of Gene Ontology biological process
(GO:BP) terms such as smoothened signaling pathway and tissue
morphogenesis (Supplementary Figures 3j,k). Irrespective of
the exact mechanism, we demonstrate that the paradoxical
increase of organoid size after inhibition of EP300/CREBBP
bromodomains may be explained by upregulation of Lgr5, Egr1,
and genes associated with developmental processes, at the cost of
IEC differentiation.
GSK-LSD1 Broadly Affects IEC
Composition
So far, we have used organoid size as a probe selection criteria.
Additionally, we performed qRT-PCR on 12 genes associated
with specific cell lineages (Haber et al., 2017). We found
that, after our positive control VPA, treatment with GSK-
LSD1 leads to the largest perturbation of the IEC lineage
marker profile as determined by calculating the Euclidean
distance of the gene expression xfold changes relative to
DMSO treatment (Figure 4A, Supplementary Figures 4a,f–k).
Flow cytometry screening of inhibitor treated organoids showed
primarily moderate changes in surface marker expressions
(Supplementary Figures 4b,c). Although GSK484 and SGC0946
caused themost perturbation in surface marker populations, they
showed little effect by qRT-PCR and thus we did not pursue
these probes further (Supplementary Figures 4d,e). Treatment
with GSK-LSD1markedly reduced gene expression of Paneth and
goblet cell markers, but caused an increase in enteroendocrine
and tuft cell marker genes, particularly Gfi1b (Figure 4B). This
supports our recent work in which we found that Lysine-
specific Demethylase 1A (LSD1, KDM1A) is required for Paneth
cell differentiation and contributes to goblet cell differentiation
(Parmar et al., 2020; Zwiggelaar et al., 2020). Paneth cells
are commonly gated as SSChi CD24+ population in flow
cytometry (Sato et al., 2011). In line with a strong reduction
of the Paneth cell marker genes Lyz1 and Defa22, we find this
population significantly reduced in GSK-LSD1 treated organoids
(Figures 4B,C). Furthermore, we observed that the pattern of
CD24+ expressing cells in GSK-LSD1 treated organoids differs
from control organoids in flow cytometry, with increase of a
SSClo_CD24hi population (Figure 4C). This pattern change was
even more pronounced in SI crypt IECs from Villin-Cre+ Lsd1f/f
mice, which conditionally lack Lsd1 in IECs, compared to wild
type (WT) littermates (Figure 4D). Similar gating has previously
been associated with enteroendocrine cells and their progenitors
(Sato et al., 2011), which thus fits with our previous observation
that enteroendocrine progenitors such as Neurod1 and Neurog3
are upregulated in Villin-Cre+ Lsd1f/f mice (Zwiggelaar et al.,
2020). However, upon performing intracellular flow cytometry
staining for the canonical tuft cell marker DCLK1, we found
that also a DCLK1hi population fell within this gate and is
increased in Lsd1-deficient crypts (Figure 4E). In support, there
was a modest yet significant increase of DCLK1+ cells in
duodenal tissue sections as well as colon sections from Villin-
Cre+ Lsd1f/f mice compared to WT littermates (Figure 4F,
Supplementary Figure 4l). Together, this example highlights
that the epigenetic probe library contains inhibitors that are able
to completely mimic the phenotype that is seen upon genetic
deletion in vivo.
BET Inhibition Reduces Relative
Abundance of Tuft Cells
Secretory cell lineage differentiation, such as goblet and Paneth
cells, is well-studied and is generally thought to involve NOTCH-
mediated lateral inhibition. Tuft cell differentiation, however,
is less defined. Therefore, we next focused on the BRD/BET
inhibitors (+)-JQ1 and bromosporine in our marker gene
expression dataset (Figure 4A) as treatment with these led to a
strong reduction of tuft cell marker genes Dclk1, Trpm5, and
Gfi1b (Figure 5A). Organoids treated with these probes also had
altered expression in some of the other IEC lineage marker
genes, but the downregulation of tuft cell marker genes was
consistent and prominent (Supplementary Figure 5a). Although
probe A-366, an inhibitor of Euchromatic histone-lysine N-
methyltransferase 1 and 2 (EHMT1/2, GLP/G9A) also reduced
tuft cell marker genes, two other EHMT1/2 inhibitors, UNC0638
and UNC0642, did not (Figure 4A, Supplementary Figure 4k).
(+)-JQ1 inhibits Bromodomain-containing protein 2 (BRD2),
BRD3, BRD4, and BRDT while bromosporine is a pan-
bromodomain inhibitor. In our hands, these two probes did
not affect overall organoid growth in the 96 h course of the
screen experiment (Supplementary Figures 2a, 5B), but (+)-
JQ1 treatment affected organoid morphology when inhibitor
treatment was continued after passaging (Figure 5B). Others
have reported that (+)-JQ1 treatment strongly reduced the
efficiency of crypts to form organoids (Bolden et al., 2014).
Tuft cell quantification after treatment of Hpgds2-tdTomato
reporter organoids indeed confirmed a complete lack of tuft
cell differentiation in organoids treated with either (+)-JQ1
or bromosporine (Figures 5B,C), suggesting that BRD proteins
are necessary for the tuft cell lineage. BRD2, BRD3, BRD4,
and BRDT are mutual targets of (+)-JQ1 and bromosporine,
of which BRDT is not expressed in SI crytps or organoids
(Supplementary Figure 5c). Interestingly, the BRD2/4 inhibitor
PFI-1 did not cause marked changes in tuft cell marker
gene expression in our screen (Supplementary Figure 5d). To
investigate the role of specific BRDs in tuft cell differentiation in
future studies may be worthwile.
Inhibition of Type I PRMTs Results in
Higher Relative Abundance of Secretory
Cells and Prevents Growth of Tumor
Organoids
So far, we focused on inhibitors that caused reduced IEC
differentiation. However, two probes stood out because they
increased the expression of genes associated with Paneth-,
goblet-, and enteroendocrine cells (Figure 4A). Of these two,
the pan-PARP inhibitor olaparib also had a marked effect
on median organoid size and abundance of LGR5+ stem
cells (Figures 2C–E). The other probe is MS023, which is
an inhibitor of type 1 protein arginine methyltransferases
(PRMTs) such as PRMT1, PRMT3, PRMT4 (CARM1), and
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FIGURE 4 | GSK-LSD1 broadly affects IEC composition. (A) Gene expression of organoids treated with DMSO or inhibitors for 96 h, measured by qRT-PCR. Color
scale represents log2 of median of xfold change relative to DMSO-treated organoids of 4 biol. replicates. IEC lineage marker genes are indicated on x-axis. Inhibitor
class is indicated on y-axis. Clustering tree is based on Euclidean distance. Log2 of the Euclidean distance (“perturbation”) is indicated in the right panel, the line at
(Continued)
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FIGURE 4 | x = 1.5 indicates inhibitors that were followed up in further experiments. Samples treated with HDAC inhibitors and gene Defa22 were excluded from the
analysis. Euclidean distance including Defa22 is shown in Supplementary Figure 4a. (B) Gene expression of organoids treated with GSK-LSD1 for 96 h measured
by qRT-PCR. xfold change relative to DMSO-treated organoids. 4 biol. replicates, indicated by shape. Median highlighted. (C) Flow cytometry of organoids treated
with DMSO or GSK-LSD1 for 96 h. Gating of representative replicates (left) and normalized frequencies of SSChi_CD24+ and SSClo_CD24hi populations of 5 biol.
replicates, indicated by shape. Mean highlighted. Paired t-test (right). (D) Flow cytometry of small intestinal crypts isolated from Villin-Cre+ Lsd1fl/fl (KO) mice with
intestine-specific deletion of Lsd1 or wild type (WT) littermates. Gating of representative replicates (left) and frequencies of SSChi_CD24+ and SSClo_CD24hi
populations of 2/2 mice (right). (E) Frequency of DCLK1+ cells measured by intracellular flow cytometry in small intestinal crypts from WT and KO mice. Overlay of
positive cells for secondary anti-rabbit staining, representative replicate (left). Quantification of intracellular staining with rabbit anti-DCLK1 primary antibody or control
in small intestinal crypts isolated from WT or KO mice. 3/2 mice. Minimum 7,000 viable cells in parent gate (right). (F) DCLK1+ cells per crypt-villus pair in duodenum
of WT and KO mice. Immunohistochemistry staining of tissue sections. Representative staining (left) and quantification in 3/3 mice, mean highlighted. Unpaired t-test
(right).
FIGURE 5 | BET inhibition reduces relative abundance of tuft cells. (A) Gene expression of tuft cell marker genes of organoids treated with DMSO, (+)-JQ1, or
bromosporine for 96 h, measured by qRT-PCR. xfold change relative to DMSO-treated organoids. 4 biol. replicates, indicated by shape. Median highlighted. Paired
t-test. (B) Representative Hpgds-tdTomato tuft cell reporter organoids treated with DMSO, (+)-JQ1, or bromosporine for 8 days with one passage. 10x magnification,
max. intensity projection. (C) Tuft cell density in Hpgds-tdTomato organoids with DMSO, (+)-JQ1, or bromosporine for 8 days. Each dot represents one organoid.
Unpaired t-test.
PRMT8 (Eram et al., 2016) (Figure 6A). Of note, two other
PRMT inhibitors in our probe library, SGC707 and MS049 that
inhibit PRMT3 and PRMT4/PRMT6, respectively, did not cause
similar effects (Supplementary Figure 6a). Although MS023-
treated organoids were moderately yet significantly smaller
than control organoids and Lgr5 gene expression was reduced,
frequency of Lgr5-EGFP stem cells was not significantly affected,
and organoids treated for 96 h would renew normally after
splitting (Supplementary Figures 6b–d). The upregulation of
secretory cell marker genes by the inhibitors was reflected by
relative cell abundance of the respective lineages in MS023-
treated versus control organoids. SSChi_CD24+ Paneth cells
appeared more frequent in MS023 treated organoids in our
flow cytometry screen (Figure 6B, Supplementary Figure 4c),
and quantification of MUC2+ goblet cells showed a trend
in the same direction (Figure 6C). Furthermore, we treated
enteroendocrine cell reporter organoids with MS023 and found
an increased frequency of Neurog3-RFP+ cells compared to the
DMSO control (Figure 6D). To get a more detailed overview of
how MS023 affects organoids, we performed mRNA sequencing
of untreated vs. MS023 treated organoids. We found 462 genes
upregulated and 457 genes downregulated with a log2 fold
change cutoff of 0.5 and padjust≤ 0.01 (Figure 6E). Importantly,
GSEA of cell-lineage specific gene sets confirmed that MS023-
treated organoids have a transcriptome that is enriched
for secretory cell lineages (Figure 6F). However, GSEA also
indicated an enrichment for genes associated with enterocytes
(Figure 6F). Thus, rather than specifically affecting secretory
cells, differentiation of all IEC cell lineages seems to be increased
in MS023 treated organoids, potentially at the cost of progenitor
cells. This is in agreement with positive enrichment of GO:BP
terms related to nutrient uptake and response to microbials
(Supplementary Figures 6e,f), which are associated with mature
enterocytes and Paneth cells, respectively. DNA repair, which
is a well established function of type I PRMTs (Guccione and
Richard, 2019), was among the negatively correlated GO:BP
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FIGURE 6 | Inhibition of type I PRMTs leads to more mature organoids and prevents adenoma growth. (A) Gene expression of organoids treated with MS023 for 96 h
measured by qRT-PCR. xfold change relative to DMSO-treated organoids. 4 biol. replicates, indicated by shape. Median highlighted. (B) Frequency of SSChi_CD24+
Paneth cells in organoids treated with MS023 for 96 h, normalized to DMSO treatment, measured in flow cytometry screen (Supplementary Figure 4c). 3 wells/2
biol. replicates, indicated by shape. Mean highlighted. (C) Density of MUC2+ goblet cells in organoids treated with DMSO or MS023 for 96 h. Median of 3 biol.
replicates, indicated by shape. Each value is the median of 4-11 organoids quantified. Paired t-test. (D) Frequency of enteroendocrine/enteroendocrine progenitor
Neurog3-RFP+ cells in reporter organoids treated with DMSO or MS023 for 96 h, measured by flow cytometry. Representative gating and quantification in 3 biol.
replicates, indicated by shape. Paired t-test. (E) Volcano plot of mRNA sequencing of untreated vs. MS023 treated organoids, 3 biol replicates per group. Selected
genes are highlighted. (F) mRNA sequencing of untreated vs. MS023 treated organoids. GSEA for Paneth cell, goblet cell, enteroendocrine cell, and tuft cell signatures
from Haber et al. (2017) (GSE92332). Normalized enrichment scores (NES) and false discovery rates (FDR) are indicated. (G) Apc-deficient adenomas treated with
DMSO, MS023, or TC-E5003 for 96 h. Representative well (top, full well shown in Supplementary Figure 6j, scale bar shows 500 µm) and quantification of organoid
size and mean gray value, 7 individual wells per condition (bottom). (H) Organoids treated with DMSO, MS023, or TC-E5003 for 96 h. Representative replicate (top, full
well-shown in Supplementary Figure 6k, scale bar shows 500 µm) and quantification of organoid size and mean gray value, 3 biol. replicates per condition (bottom).
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terms (Supplementary Figures 6e,g). We found that PRMT1
was the type I PRMT with the highest gene expression level in
SI crypts and organoids (Supplementary Figure 6h). Enhanced
PRMT levels are found in various malignancies and high
PRMT1 expression is negatively correlated with survival in colon
cancer (Mathioudaki et al., 2008; Jarrold and Davies, 2019).
Furthermore, Prmt1 gene expression was highest in ISC, transit-
amplifying cells, and early enterocyte progenitors compared
to fully differentiated lineages in a published IEC scRNA-seq
dataset (Haber et al., 2017) (Supplementary Figure 6i). We
therefore hypothesize that inhibition of type I PRMTs leads
to maturation of IECs, which aligns with the observation
that differentiated cells have lower Prmt1 levels. To test if
PRMT type I inhibition could hence be used therapeutically
to force progenitors, such as those found in WNT-driven
tumors, to mature or differentiate, we treated Apc-deficient
organoids with MS023 or the PRMT1-specific inhibitor TC-
E5003. MS023 treated adenomas were smaller and darker
than adenomas treated with DMSO control, and TC-E5003
treatment almost completely hindered their growth (Figure 6G,
Supplementary Figure 6j). Yet, these probes did not cause
growth inhibition of wild type organoids nor did they
reduce cell viability (Figure 6H, Supplementary Figures 6k,l).
In summary, we show that inhibition of type I PRMT leads
to more differentiated organoids and has the potential to
hinder proliferation in intestinal tumor organoids, making it an
attractive candidate to pursue in future studies.
DISCUSSION
Working with heterogeneous organoid cultures is challenging
with respect to reproducibility and quantification. Our toolkit,
which we present in this article enables reproducible results
across biological replicates using standard equipment and is
suitable for screening setups. We established a quantification
workflow that is based on the open source tools ImageJ and
Ilastik, which is a simple yet robust alternative to recent stand-
alone software options (Borten et al., 2018; Kassis et al., 2019) and
could easily be adapted to different tissue organoids. In addition,
qRT-PCR and flow cytometry of IEC lineages is sufficiently
sensitive for initial screening and was subsequently confirmed
by additional methods such as reporter organoids. We used this
screening setup to test a set of 39 chemical probes targeting
epigenetic modifiers and identified probes that strongly affected
organoid size or IEC lineage composition. These new regulators
of intestinal epithelial biology are highly interesting candidates
for further mechanistic studies.
Probes targeting EP300/CREBBP were designed as cancer
therapeutics (Attar and Kurdistani, 2017). Thus, we were
surprised to find that inhibition of P300/CREBBP led to
an increase of organoid size, which was supported by an
expansion of LGR5+ cells and reduction of differentiation
(Figure 3). EP300/CREBBP mediate acetylation of histone
H3K27 at enhancer elements and promoters, and can act as a
transcriptional co-activator with numerous transcription factors
(Goodman and Smolik, 2000; Ramos et al., 2010; Wang et al.,
2013; Raisner et al., 2018; Weinert et al., 2018). In support of a
general activating role for EP300/CREBBP, we found that the
majority of genes altered by I-CBP112-treatment were down-
regulated (Figure 3D), and many of these genes are established
targets of EP300/CREBBP-associated transcription factors.
EP300/CREBBP is a well established co-activator of signaling
cascades that control cell proliferation, including WNT, NFκB,
or MYB signaling. Although we cannot rule out that altering
these interactions might contribute to enhanced organoid
growth, transcriptional signatures associated with β-Catenin
(Ctnnb1), NFκB-subunit RelA, or MYB were downregulated
after treatment with the EP300/CREBBP inhibitor I-CBP112
(Supplementary Figure 3h). It is difficult to separate the
epigenetic modifier (H3K27 acetylation) from the transcriptional
co-activator role of EP300/CREBBP, especially since a recent
study showed a central role for the bromodomain and HAT
domain also for the EP300/CREBBP transcription factor binding
capacity (Ortega et al., 2018). Nevertheless, underlining the
critical role of the bromodomain, plt6-mice that carry a mutation
in the EP300KIX domain, which specifically prevents interaction
of EP300 with the transcription factor MYB, displayed reduced
cell proliferation in the intestine (Sampurno et al., 2013). The
EP300/CREBBP bromodomain is critically required for H3K27
acetylation at enhancer elements, a mark of active enhancers, and
its inhibition leads to reduced expression of enhancer-proximal
genes (Creyghton et al., 2010; Raisner et al., 2018). In the adult
small intestine, Sheaffer et al. (2014) described a gain of H3K27Ac
at dynamically methylated enhancer sites in differentiated IECs
but not LGR5+ ISC. Furthermore, Kazakevych et al. (2017)
found that H3K27Ac positive distal elements were a good
indicator for cell identity and differentiation status whereas
genes positively regulating proliferation were transcribed in
most IEC types. EP300/CREBBP has previously been shown
to be required for differentiation of embryonic stem cells,
muscle cells, and adipocytes (Puri et al., 1997; Zhong and Jin,
2009; Namwanje et al., 2019). In turn, Ebrahimi et al. (2019)
recently described that EP300/CREBBP maintains transcription
of fibroblast-specific somatic genes and that EP300/CREBBP
bromodomain inhibition can promote cellular reprogramming
to pluripotency, accompanied by decrease in promoter- and
enhancer-associated H3K27 acetylation. We provide evidence
that EP300/CREBBP inhibition in the intestinal epithelium
can promote proliferation rather than preventing it. It appears
plausible that EP300/CREBBP bromodomain activity is critically
required to enable transcription of IEC differentiation genes and
that in its absence the intestinal epithelium remains immature,
accompanied by an enhanced proliferative capacity.
We recently demonstrated a central role of LSD1 in Paneth
and goblet cell differentiation and maturation (Parmar et al.,
2020; Zwiggelaar et al., 2020). Here, we confirm the critical
role of LSD1 for IEC lineage differentiation in an unbiased
screen and in addition provide indications that instead of
Paneth/goblet cells there is an expansion of DCLK1+ tuft
cells that is associated with a CD24high_SSClow population by
flow cytometry (Figure 4). In contrast, we find that treatment
with the BRD/BET inhibitors (+)JQ-1 and bromosporine
completely blocks tuft cell differentiation (Figure 5). Tuft cells
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are important mediators of intestinal type 2 immunity (Gerbe
et al., 2016; von Moltke et al., 2016). Our work matches
observations of two studies that found that inhibition of the
BET bromodomain in vivo abolished tuft cells (Bolden et al.,
2014; Nakagawa et al., 2016). Using a different BRD/BET probe,
Nakagawa et al. (2016) described that the absence of tuft
cells was due to blockade of transit-amplifying cells as their
intermediate progenitors. While Nakagawa et al. also found a
reduction of enteroendocrine cells, another study described an
increase of pancreatic NEUROG3+ enteroendocrine progenitors
following (+)-JQ1 treatment (Huijbregts et al., 2019). Our
findings could be the foundation of using these compounds to
modulate immune responses, especially when a type 2 response
is unfavorable.
Type I PRMT inhibition with MS023 led to a more
differentiated intestinal epithelium without major loss of LGR5+
stem cells (Figure 6, Supplementary Figure 6c). PRMT1 was the
most highly expressed type I PRMT and is higher expressed
in ISCs and progenitors compared to differentiated cells
(Supplementary Figures 6h,i). An evolutionary conserved role
of PRMT1 in the adult intestine has been proposed earlier
as endogenous PRMT1 knockdown reduces the adult ISC
population in Xenopus and zebrafish, while transgenic PRMT1
overexpression leads to an increase of ISCs (Matsuda and Shi,
2010; Ishizuya-Oka and Shi, 2011). Furthermore, our observation
is very similar to findings of enriched PRMT1 in epidermis
progenitors, required for maintenance of this population (Bao
et al., 2017). Bao et al. (2017) proposed that PRMT1 is both
involved in the maintenance of progenitor/proliferative genes as
well as the repression of “differentiation” genes. In agreement
with the latter, we found increase of all differentiated IEC lineages
after treatment with MS023 (Figures 6A–F). PRMT1 has a wide
substrate specificity and mediates both arginine methylation of
histones such as H4R3, and non-histone proteins (Huang et al.,
2005; Lehman et al., 2020). Elevated PRMT1 expression is found
in several cancer types and is associated with poor prognosis
and chemoinsensitivity (Altan et al., 2016; Musiani et al., 2020)
and pharmacological PRMT inhibitors have recently gained
interest as drug candidates for cancer treatment (Guccione and
Richard, 2019; Jarrold and Davies, 2019). Targeting cancer stem
cells (CSCs) in the gut comes with the challenge that following
ablation of LGR5+ CSCs, LGR5- cells have the potential to de-
differentiate to CSCs (Morgan et al., 2018). Therefore, forcing
differentiation of cancer cells could be an attractive treatment
strategy. Indeed, we found that PRMT type I inhibition with
MS023 and PRMT1-specific inhibition with TC-E5003 severely
impaired growth of Apc-deficient tumor organoids but not
normal organoids (Figures 6G,H). A conditional Prmt1-deficient
mouse was recently generated (Choi et al., 2019). Crossing
these mice with intestine-specificVillin-Cre or tumor-developing
Apcmin mice, could be an elegant way to further study the role of
PRMT1 in IEC differentiation and maturation and to investigate
the therapeutic potential of PRMT1 inhibition for the treatment
of intestinal cancer.
Highly permissive chromatin and transcriptional control of
IEC fate, as well as gene regulation by differential chromatin
states, have been discussed as opposing models of intestinal
epithelial differentiation regulation (Elliott and Kaestner, 2015).
Testing a library of highly selective inhibitors targeting more
than 20 epigenetic modification enzymes/enzyme families, only
two HDAC-inhibitors prevented organoid growth (Figure 2)
and the majority of the tested probes did not alter organoid
growth or IEC composition. However, we found that few
compounds resulted in pronounced changes and these were
associated with generally less (EP300/CREBBP, LSD1 inhibition)
or more (PRMT type I inhibition) epithelial differentiation. We
therefore propose that epigenetic modifiers control the degree
of intestinal epithelial differentiation in general, rather than
affecting specific cell lineage fate. Whether this parallels the
postnatal maturation of the fetal intestinal epithelium remains
to be elucidated. Of note, the epigenetic modifiers identified to
affect IEC differentiation in our screen share the capacity to
both modify histones and to interact with multiple transcription
factors. Thus, these molecules could be a key link connecting the
epigenetic and the transcriptional layers of gene regulation in the
intestinal epithelium. Indeed, work by others supports a model
of tightly intertwined epigenetic and transcriptional control and
shifting between permissive and dynamic chromatin on a local
instead of a global scale. By integrating the investigation of
gene expression, open chromatin, and DNA hydroxymethylation
in IEC populations with differential expression levels of the
transcription factor SOX9, recent elegant work by Raab et al.
(2020) identified either highly permissive or dynamic chromatin
states at given loci relative to transcription factor binding. EP300
has been described to potentiate SOX9-dependent transcription
(Furumatsu et al., 2005) and Sox9-deficient intestinal epithelium
fails to mature (Bastide et al., 2007). Mapping of EP300-binding
sites was recently utilized to identify transcriptional networks in
specialized cell types in the placenta (Lee et al., 2019), inspiring
further investigation of epigenetic modifier-aided transcription
in different IEC lineages.
To summarize, we developed a resource that allows to
compare the requirement of various epigenetic modifiers
for intestinal epithelial renewal and IEC differentiation. Our
results indicate that some epigenetic modifiers with the
capacity to both mediate histone modifications and act as
transcriptional co-regulators control the balance between an
undifferentiated/differentiated epithelial state. Thereby, they lay
basis for a fine-tuned transcriptional regulation and rapid
adjustment upon injury or pathogenic challenge.
METHODS
Epigenetic Modifier Inhibitors
The epigenetic modifier inhibitors in the screen experiment
were part of the Structural Genomics Consortium Epigenetic
Chemical Probes Collection as of March 2016. Probes were
reconstituted in DMSO and used at the recommended
concentration as listed in Supplementary Table 1. 1 mM
valproic acid (VPA) was included as positive control. DMSO
vehicle control was matched to the highest concentration used
per experiment, maximal 10 µM. PRMT1-specific inhibitor
TC-E5003 (Santa Cruz Biotechnology, # sc397056) was included
in follow-up experiments and used at 50 µM, equivalent to 10
µMDMSO.
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Mice
C57BL/6JRj wild type (Janvier labs), Lgr5-EGFP-IRES-CreERT2
(Jackson Laboratories, stock no: 008875), Villin-Cre (el Marjou
et al., 2004) (kind gift from Sylvie Robine), Lsd1f/f (Kerenyi
et al., 2013) (kind gift from Stuart Orkin), and Apc15lox
(Jackson Laboratories, stock no: 029275) mice were housed
under specific-pathogen free conditions at the Comparative
Medicine Core Facility (CoMed), Norwegian University of
Science and Technology, Norway. For the flow cytometry
screening experiment, organoids were generated from C57BL/6
mice housed at the Leibniz-Forschungsinstitut für Molekulare
Pharmakologie, Germany. Hpgds-tdTomato mice (Bornstein
et al., 2018) were housed at University of Montpellier, France.
Neurog3-RFP mice (Kim et al., 2015) (kind gift from Anne
Grapin-Botton) were housed at University of Copenhagen,
Denmark. Experiments were performed following the respective
legislation on animal protection, were approved by the local
governmental animal care committee, and were in accordance
with the European Convention for the Protection of Vertebrate
Animals used for Experimental and other Scientific purposes.
Small Intestinal Crypt Isolation
Small intestinal crypts were isolated as described previously (Sato
and Clevers, 2012). The proximal half of the small intestine was
rinsed, opened longitudinally, cut to small pieces after villi and
mucus were scraped off, washed with PBS until the solution was
clear, and incubated in 2 mM EDTA/PBS for 30 min at 4◦C with
gentle rocking. Fragments were subsequently washed with PBS
and the crypt fraction was typically collected from wash 2–5. All
centrifugation steps were carried out at 300× g.
Organoid Culture
Organoids were generated by seeding ca. 250–500 small intestinal
crypts in a 50 µl droplet of cold Matrigel (Corning #734-1101)
into the middle of a pre-warmed 24-well plate. Matrigel was
solidified by incubation at 37◦C for 5–15 min and 500 µl culture
medium added. Basal culture medium (“ENR”) consisted of
advanced DMEM F12 (Gibco) supplemented with 1x Penicillin-
Streptomycin (Sigma-Aldrich), 10 mMHEPES, 2 mMGlutamax,
1x B-27 supplement, 1x N2 supplement, (all Gibco) 500 mM
N-Acetylcysteine (Sigma-Aldrich), 50 ng/ml recombinant EGF
(Thermo Fisher Scientific), 10% conditioned medium from a
cell line producing Noggin (kind gift from Hans Clevers),
and 20% conditioned medium from a cell line producing R-
Spondin-1 (kind gift from Calvin Kuo). ENR culture medium
was replaced every 2–3 days. Organoids were passaged at 1:3–1:4
ratio by disruption with rigorous pipetting almost to single cells.
Organoid fragments were centrifuged at 300× g, resuspended in
40–50 µl cold Matrigel per well, and plated on pre-warmed 24-
well plates. Organoids derived from different mice or a repetition
at least one passage apart are considered biological replicates.
Technical replicates, i.e., separate wells, were carried out in some
experiments and were pooled for analysis.
Altering IEC Lineage Composition in
Organoids
Protocols to alter the IEC composition in organoids have been
described previously (Yin et al., 2014; Kishida et al., 2017; Luu
et al., 2018). Organoids were grown for 48 h in ENR or ENR
+ 3 µM CHIR99021 (Sigma-Aldrich) and 1 mM valproic acid
(VPA). Then, media was replaced by ENR, ENR + 3 µM CHIR
and 1 mM VPA, ENR + 3 µM CHIR and 10 µM DAPT, or
ENR + 10 µM DAPT and 2 µM IWP2. VPA, DAPT, IWP2 were
purchased from Cayman Chemicals. Organoids were harvested
72 h after media change.
Organoid Screen With Epigenetic Chemical
Probes Library
Organoids of four biological replicates were passaged to nearly
single cells at 1:4 ratio as described above and seeded in 40 µl
Matrigel droplets in 24-well plates. 250 µl/well ENR were added
immediately after solidification and 250 µl/well ENR + probes
at 2x working concentration (see Supplementary Table 1) were
added within 30 min. For each biological replicate DMSO vehicle
controls were carried out in quadruplicates. Media was replaced
after 48 h. Organoids bright-field images were acquired daily on
an EVOS2 microscope and after 96 h RNA was harvested.
Reporter Organoids
Lgr5-EGFP organoids were generated as described above from
Lgr5-EGFP-IRES-CreERT2 mice and maintained for no longer
than 3 weeks. Organoids were grown in ENR or ENR +
3µM CHIR99021 (Sigma-Aldrich) as indicated and Lgr5-
EGFP+ cells were quantified using a BD LSRII flow cytometer
(Becton Dickinson) as percentage of viable cells. Tuft cell
reporter organoids were generated from Hpgds-tdTomato mice
(expressing tdTomato under the Hpgds promoter) as described
above. Hpgds-tdTomato+ cells were quantified by confocal
microscopy on an Axio Imager Z1 microscope (Zeiss) as number
of cells relative to the organoid area after z-stack projection,
determined by nuclear staining. Enteroendocrine cell reporter
organoids were derived from the proximal small intestine
of Neurog3-RFP mice (expressing RFP under the Neurog3
promoter) and cultured as described above using recombinant
murine Noggin (100 ng/ml, Peprotech) and 10% R-Spondin
conditioned medium. Neurog3-RFP+ cells were quantified using
a BD FACSAria III flow cytometer (Becton Dickinson) as
percentage of viable cells.
Modified Organoid Growth Conditions With
EP300/CREBBP Inhibition
Lgr5-EGFP organoids were grown in ENR or ENR + 3 µMCHIR
for 96 h. Media was replaced after 48 h. To investigate low growth
factor conditions, wild type organoids were grown in ENR or
ENR with 1% R-Spondin, ENR with 5 ng/ml EGF, or ENR + 2
µM IWP2 for 192 h. Media was replaced every 48 h.
Splitting of Organoids After Type I PRMT
Inhibition
Organoids were treated with DMSO or MS023 for 96 h, passaged
to nearly single cells as described above, and cultured in ENR for
additional 96 h. Media was replaced every 48 h.
Generation of APC-Deficient Adenomas
Eight week old Apc15lox × Lgr5-EGFP-IRES-CreERT2 mice were
administered 2 mg Tamoxifen in corn oil (both Sigma-Aldrich)
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for 5 consecutive days. Adenomatous polyps developed over
the course of a month (ethically approved by the Norwegian
Food Safety Authority, FOTS ID: 15888). To generate adenoma
organoids, the small intestine was rinsed with PBS, opened
longitudinally, polyps were excised, cut into small pieces, and
washed in PBS. Next, 5 ml TrypLE express (Thermo Fisher
Scientific) was added and incubated for 30 min at 37◦C while
pipetting every 5–10 min. After incubation, single cells were
obtained by passing the supernatant through a 40 µm strainer.
Single cells were plated in 50 µl cold Matrigel on a pre-warmed
24-well plate, and cultured in basal culture medium lacking
R-Spondin-1 (“EN”). EN culture medium was replaced every
2–3 days.
Organoid Growth Quantification
Organoid bright-field images were acquired on an EVOS2
microscope (Thermo Fisher Scientific) with 2x magnification. At
the starting point of the experiment, for each plate an automation
setup was generated to acquire z-stacks with 50 µm spacing
either of a single position or 2–4 tiled images covering height and
most area of the Matrigel dome for each well. This automation
setup was reused at consecutive timepoints. A custom ImageJ/Fiji
v1.52n (Schindelin et al., 2012, 2015) macro was used to
collect single positions and layers for each well, to save a stack
(ImageJ bright-field stack) and projections, and to perform a
simple organoid segmentation (“ImageJ workflow”). For the
segmentation, a Sobel edge detector was applied to each z-stack
layer (ImageJ edge stack), a standard deviation z-projection of
the edge stack was generated, and particle analysis with optional
manual correction was performed after several binary operations
and thresholding. For an improved segmentation that is robust to
stitching artifacts, allows to filter out debris and organoid clusters
and to distinguish different organoid phenotypes, the ImageJ
workflow was combined with the interactive machine learning
software Ilastik v1.3.2 (Berg et al., 2019) (“combined workflow”).
Training data was taken from the analyzed experiment and
excluded from further analysis. In a first step, pixel classification
on an intensity summary projection of the ImageJ edge stack
was used to separate between background and object outlines.
The generated pixel prediction maps were then used as input
in a second step of object classification together with minimum
projections of the ImageJ bright-field stack. Routinely, the
following label classes were used: Organoid, big sphere, small
sphere, cluster, debris, background mislabeled as organoid, air
bubble, edges of well plate. Objects classified in the latter three
object classes were excluded from all timepoints, objects classified
as debris or cluster were excluded from 72 to 96 h timepoints.
Representative images were arranged using GNU R packages
magick and ggimage.
RNA Isolation, Quantitative RT-PCR, and
Analysis
To harvest RNA, organoids in the Matrigel dome were dissolved
in 250 µl RNA-solv reagent (Omega Bio-Tek). RNA was
isolated using Direct-zol-96 RNA or Direct-zol MiniPrep kit
(Zymo Research) according to the manufacturer’s instructions,
including DNAse digestion. cDNA was transcribed using High-
Capacity RNA-to-cDNA Kit (Applied Biosystems) according to
the manufacturer’s instructions. RNA quality and concentration
was assessed on an NanoDrop-1000 instrument (NanoDrop).
Samples were handled in 96-well plates and transferred with
multichannel pipettes. qRT-PCR was carried out in technical
duplicates in 384-well plates on a QuantStudio 5 instrument
(Thermo Fisher Scientific) using 2x Perfecta ROX,UNG Fast
Mix (Quanta Biosciences) and 5 ng cDNA per reaction in a
total volume of 12 µl. Primer-probe combinations were selected
based on the Universal Probe Library System (Roche) and
are listed in Supplementary Table 2, primers were purchased
from Sigma-Aldrich. Hprt was used as housekeeping gene.
1CT values were calculated as 1CT = CT (housekeeping
gene)-CT (gene of interest) (such that higher values indicate
higher relative expression); 11CT values referred to the
calibrator as indicated, and fold change was calculated as
211CT. Target gene “perturbation” was calculated as Euclidean
distance of the log2 median fold change using GNU R
package pheatmap. Defa22 gene expression was below the
detection limit for some samples and was therefore omitted
from the Euclidean distance ranking but is provided in the
Supplementary Material.
Flow Cytometry
To obtain single cells, Matrigel in 1–3 wells was disrupted
by pipetting, well content was transferred to an Eppendorf
tube, centrifuged at 300× g, and supernatant removed. Then,
organoids were incubated with 300 µl TrypLE express (Thermo
Fisher Scientific) for 37◦C for 30 min and pipetted up/down with
a 1,000 µl pipet tip prior to and after the incubation. Single
cells were stained with Zombie Aqua (Biolegend, 1:1,000 in PBS)
for 15 min at room temperature (RT) for live-dead exclusion. If
DAPI instead of Zombie Aqua staining was used for live-dead
exclusion, it was added it during the last washing step (1:1,000).
Samples were incubated with antibody conjugates against
CD326-BV605, CD24-PerCp-Cy5.5 or AF647, CD44-BV785,
CD117-PE-Cy7 [all Biolegend, see Supplementary Table 3 for
detailed list, 1:200 in PBS + 2% fetal calf serum (FCS)],
and Ulex Europaeus Agglutinin (UEA)1-Rhodamine (2 µg/ml,
Vector Laboratories #RL-1062-2) for 20 min at 4◦C. For
intracellular staining, samples were subsequently fixed with 2%
paraformaldehyde (PFA) for 15min, and incubated with or
without rabbit anti-DCLK1 (Abcam #ab31704, 1:500 in PBS/2%
FCS/0.05% Saponin) for 1 h at 4◦C, followed by incubation
with Goat anti-Rabbit IgG-AF405 (Invitrogen, 1:1,000 in PBS
+ 2% FCS + 0.05% Saponin). Samples were analyzed on a
BD LSRII instrument (Becton Dickinson) equipped with 405,
488, 561, 647 nm laser lines. Single fluorochrome stainings
of cells and compensation particles (BD CompBead, Becton
Dickinson) were included in each experiment. For analysis,
FlowJo software v10.6.2 and GNU R/Bioconductor v3.6.3/v3.10
packages flowCore, CytoML/flowWorkspace, ggcyto, flowViz
were used (Van et al., 2018). If not indicated otherwise, only
samples with more than 10,000 viable cells in the parent gate
were included.
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Flow Cytometry Screening
For the flow cytometry screening experiment, organoids were
grown in 96 well glass-bottom plates (Cellvis) that were pre-
cooled and held on ice during seeding. Organoid fragments
in Matrigel (50 µl/well) were distributed in pre-cooled plates
with an automated pipette, then plates were transferred to a
rotary plate shaker for 30 s at 150 rpm, before the Matrigel
was solidified at 37◦C. With help of a Viaflo 96-channel pipette
(Integra Biosciences) 200 µl/well ENR without or with inhibitors
were added of which 100 µl were replaced daily during the 96 h
time course. To obtain single cells, culture media was removed,
100 µl/well TrypLE express (Thermo Fisher Scientific) added
andMatrigel disrupted by repeated pipetting with a multichannel
pipette. Staining with Zombie Aqua, CD326-BV421, CD24
-PerCp-Cy5.5, CD44-AF647, CD117-PE-Cy7 (all Biolegend,
see Supplementary Table 3 for detailed list), and UEA1-FITC
(Invitrogen) was carried out as described above. Samples were
run on a MACSQuant X instrument (Miltenyi Biotec) equipped
with 405, 488, 647 nm laser lines and analyzed as described
above. Euclidean distance clustering tree of normalized median
population frequencies was generated with GNU R package
ggtree (Yu et al., 2018).
Confocal Microscopy and Quantification
For immunofluorescence staining, organoids were grown in 30
µl/well Matrigel droplets in a 8-well microscopy chamber (Ibidi)
that was pre-warmed for seeding. After 96 h incubation, the
organoids were fixed in 4% paraformaldehyde and 2% sucrose
for 30 min at RT, washed, and permeabilized with 0.2% Triton-
X100 in PBS. Free aldehyde groups were blocked using 100 mM
glycine, followed by blocking buffer (1% BSA, 2% NGS diluted
in 0.2% Triton-X100 in PBS) for 1 h at RT. The organoids were
incubated overnight at 4◦C with a primary antibody against
KI67 (Invitrogen #MA5-14520; 1:200) orMUC2 (Santa Cruz #sc-
15334; 1:200) in blocking buffer, followed by three washes with
slight agitation. Next, the organoids were incubated with Goat
anti-Rabbit IgG-AF488 (Invitrogen, 1:500), UEA1-Rhodamine
(Vector Laboratories #RL-1062-2, 2 µg/ml), and Hoechst 33342
overnight at 4◦C. After washing, the organoids were mounted
using Fluoromount G (Thermo Fisher Scientific), and visualized
using a LSM880 confocal microscope (Zeiss). UEA1/MUC2-
positive cells were manually counted for ≥5 organoids per
biological replicate in a middle plane of a z-stack. Cell numbers
are reported relative to the area of the z-stack projection of each





Immediately after euthanizing mice, the intestinal tissues were
removed, washed with PBS, fixed in 4% formaldehyde for 48–
72 h at RT, and embedded in paraffin wax. Staining was carried
out on 4 µm paraffin sections. The sections were rehydrated and
treated with 3% hydrogen peroxide for 10 min at RT. Antigens
were retrieved by boiling the slides in citrate buffer (pH6) in
a microwave for 15 min. For immunohistochemistry staining
of duodenum sections, the sections were incubated overnight
at 4◦C with anti-DCLK1 (Abcam #ab31704; 1:1,500) in TBS
+ 0.025% Tween 20 + 1% BSA. Specific binding was detected
with Envision-HRP (Dako) and DAB (Dako) and images were
acquired on a EVOS2microscope (Thermo Fisher Scientific) with
10x magnification. DCLK1+ cells were quantified for ≥30 crypt-
villus pairs per mouse. Representative images were acquired
on a Eclipse Ci-L microscope (Nikon) with 20x magnification.
For immunofluorescence staining of colon sections, slides were
blocked with PBS + 1% BSA + 2% goat serum + 0.2% Triton
X-100 for 1h at RT and incubated overnight at 4◦C with anti-
DCLK1 antibody (Abcam #ab31704; 1:250) in PBS + 1% BSA
+1% goat serum + 0.05% Tween 20. Specific binding was detected
with Goat anti-Rabbit IgG-AF488 (Invitrogen, 1:1,000) for 1h at
37◦C while nuclei were stained with DAPI (1:1,000). Slides were
mounted with Fluoromount G (Thermo Fisher Scientific) and
images were acquired on a LSM880 confocal microscope (Zeiss)
with 20x magnification. DCLK1+ cells were quantified for ≥50
crypts per mouse.
mRNA Sequencing
Organoid RNA was isolated and treated with DNAse with
Quick-RNA Micro prep kit (Zymo Research) according to
manufacturer’s instructions. RNA integrity numbers were found
to be ≥7. For the I-CBP112 inhibitor study, library preparation
was done using the Illumina TruSeq Stranded protocol. Library
concentrations were quantified with the Qubit Fluorometric
Quantitation system (Life Technologies) and the size distribution
was assessed using a 2100 Bioanalyzer automated electrophoresis
system (Agilent). For sequencing, samples were diluted and
pooled into NGS libraries in equimolar amounts and sequenced
at 75 bp single-read chemistry on an Illumina NS500 MO flow-
cell on a Ilumina NextSeq 500 instrument (Illumina) by the
Genomics core facility (GCF, NTNU). For the MS023 study,
library preparation was done using the NEB Next Ultra RNA
Library Prep Kit with poly(A) mRNA enrichment and samples
were sequenced at 150X2 bp paired-end chemistry on a Illumina
NovaSeq 6000 instrument by Novogene (UK) Co.
mRNA Sequencing Analysis
Read quality was assessed using FastQC v0.11.8, reads were
aligned with STAR v2.7.3a to the Mus musculus genome build
mm10, and MultiQC v1.7 was used to summarize logs from
STAR and FastQC (Dobin et al., 2013; Leggett et al., 2013; Ewels
et al., 2016). The number of reads that uniquely aligned to
the exon region of each gene in GENCODE annotation M18
of the mouse genome was then counted using featureCounts
v1.6.4 (Liao et al., 2014; Frankish et al., 2019). Genes that
had a total count <10 were filtered out. Differential expression
was then determined with GNU R/Bioconductor v3.6.1/v3.10
package DESeq2 v1.26.0 using default settings and shrunken
log2foldchange was calculated with the apeglm method (Love
et al., 2014; Zhu et al., 2019). GSEA enrichment was performed
using GNU R/Bioconductor v3.6.3/v3.10 package ClusterProfiler
v3.14.3 by shrunken log2 fold change and with the shrunken
log2 fold change as weights using 10,000 permutations (Yu
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et al., 2012). Gensets for celltype signatures were assembled
based on single-cell and bulk RNA-Sequencing data from sorted
samples based on datasets by Haber et al. (2017) (GSE92332)
and Muñoz et al. (2012) (GSE33949). Transcription factors
interacting with murine or human EP300 or CREBBP were
retrieved from protein-protein interactions with an minimum
medium experimental confidence level (≥0.4) from STRING-DB
v11 (Szklarczyk et al., 2019). Genesets regulated for the mouse
and human version of these transcription factors were retrieved
from TRRUST v2 (Han et al., 2018). For human genesets,
murine orthologue genes retrieved from Ensembl GRCh38.p13
through GNU R/Bioconductor v3.6.3/v3.10 package biomaRt
v2.42.1 (Durinck et al., 2005) were used for enrichment. Genesets
for characterization of Biological Process were directly obtained
from The Gene Ontology Consortium (2019).
Data Processing and Statistical Analysis
Data was processed and statistical analysis was carried out
with GNU R v3.6.3 using the packages tidyverse and ggpubr
(Wickham et al., 2019). Pearson correlation coefficient, and
paired or unpaired t-test were calculated as indicated, assuming
normal distribution. Median or mean are shown as indicated. In
boxplots, the box represent the 25, 50, and 75% percentiles and
whiskers represent 1.5× IQR.
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Supplementary Figure 1 | (a) Organoid growth 24-96h, representative well from
experiment quantified in Figure 1C. The area shown in Figure 1A is marked. (b)
Organoid segmentation with ImageJ/Fiji (“IJ,” left) and combined ImageJ/Fiji and
Ilastik (“Ilastik,” right) workflow, 48 and 96 h timepoints. The ImageJ segmentation
sufficiently identifies objects while the combined workflow is more accurate and
can distinguish phenotypes such as organoid, sphere, cluster, or debris. (c)
Quantification result with ImageJ workflow. Pooled data from 2 biol. replicates. (d)
Flow cytometry gating strategy. (e) Flow cytometry of organoids grown for 48 and
96 h. Population frequencies of flow cytometry staining in Cells, Cells/CD326hi and
Cells/CD24+ parent gate, 3 biol. replicates, indicated by shape, mean highlighted
(bottom). Log2 fold change normalized to 96 h timepoint, visualized as dot plot,
dot size corresponds to absolute log2 fold change (top). (f) Flow cytometry of
organoids cultured for 48 h followed by 72 h (48_72 h) with normal culture
medium (ENR_ENR), or culture medium containing CHIR+VPA_CHIR+VPA,
CHIR+VPA_CHIR+DAPT, or CHIR+VPA_IWP2+DAPT to modify IEC composition.
Population frequencies in Cells, Cells/CD326hi and Cells/CD24+ parent gate. Log2
fold change normalized to ENR_ENR treatment. 3 biol. replicates, indicated by
shape, mean highlighted (bottom) and visualized as dot plot, dot size corresponds
to absolute log2 fold change (top). (g) Flow cytometry of organoids cultured for 48
h followed by 72 h (48_72 h) as indicated. Staining of representative replicate,
fluorescence intensity median and q25 and q75 percentile. Cell count in Cells
parent gate is indicated. (h) Flow cytometry of organoids cultured for 48 h
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followed by 72 h (48_72 h) as indicated. SSC vs. CD24_PerCp-Cy5.5 staining in
Cells parent gate, frequency in SSChi_CD24+ gate is indicated.
Supplementary Figure 2 | (a) Segmentation results of combined ImageJ/Ilastik
(left) and ImageJ (right) workow of organoids treated with DMSO or inhibitors for
0–96 h. 4 biol. replicates. (b) Median organoid area and relative Lgr5 gene
expression in DMSO or olaparib-treated organoids. 4 biol. replicates, indicated by
shape. Median highlighted. Paired t-test. (c) Median organoid area and relative
Lgr5 gene expression in DMSO, CI-994, or LAQ824-treated organoids. 4 biol.
replicates. Median highlighted. Paired t-test. (d) Frequency of Lgr5-EGFP stem
cells in reporter organoids treated with DMSO or olaparib, measured by flow
cytometry. Gating of representative replicate (top) and percentage of GFP+ cells
normalized to DMSO condition of 5 biol. replicates, indicated by shape. Mean
highlighted. Paired t-test (bottom). Minimum 5,000 viable cells in parent gate.
Supplementary Figure 3 | (a) Median organoid area and relative Lgr5 gene
expression in DMSO, SCG-CBP30, or I-CBP112 treated organoids. 4 biol.
replicates, indicated by shape. Median highlighted. Paired t-test. (b) Organoids
treated with DMSO, SGC-CBP30, or I-CBP112 for 96 h. Percentage of organoids
classified as big spheres in combined ImageJ/Ilastik segmentation workflow. 4
biol. replicates, indicated by shape. Mean highlighted. Paired t-test. (c) Confocal
microscopy of DMSO, SCG-CBP30, or I-CBP112 treated organoids. 10x
magnification, max. intensity projection. Full well, the organoids shown in
Figure 2B are marked. (d) Frequency of Lgr5-EGFP stem cells in reporter
organoids grown in ENR or ENR + CHIR and treated with DMSO, SCG-CBP30, or
I-CBP112, measured by flow cytometry. Gating of representative replicate (top)
and percentage of GFP+ cells normalized to ENR DMSO condition of 3 biol.
replicates, indicated by shape. Mean highlighted. Paired t-test (bottom). (e)
Representative replicate of Lgr5-EGFP reporter organoids grown in ENR or ENR +
CHIR and treated with DMSO, SCG-CBP30, or I-CBP112 for 96 h. (f) Object area
of organoids grown in ENR, ENR + low R-Spondin (1%), ENR + low EGF (1
ng/ml), or ENR + IWP2 (Wnt pathway inhibitor) for 192 h, treated with DMSO,
SGC-CBP30, or I-CBP112. 3 biol. replicates, indicated by shape. (g)
Representative Replicate of organoids grown in ENR, or low growth factor
conditions for 192 h, treated with DMSO, SGC-CBP30, or I-CBP112. (h) mRNA
sequencing of untreated vs. I-CBP112 treated organoids. GSEA of target genes of
the convergence of murine and human transcription factors from the TRRUST
transcriptional interactions database and proteins interacting with murine or
human EP300 or CREBBP with a minimum medium experimental confidence level
(≥0.4) from the STRING protein-protein interactions database. Enriched
transcription factor target gene sets with a p-value ≥0.1 are shown. All normalized
enrichment score (NES) values are indicated. (i) mRNA sequencing of untreated
vs. I-CBP112 treated organoids. GSEA for enterocyte, Paneth cell, goblet cell,
enteroen-docrine cell, tuft cell signatures from Haber et al. (GSE92332). (j) GSEA
for Gene Ontology biological process (GO:BP) terms. Normalized enrichment
score (NES) is indicated by color. Top 50 categories are shown. (k) GSEA for
Gene Ontology term “smoothened signaling pathway” (GO:0007224, NES =
2.0406), and “tissue morphogenesis” (GO:0048729, NES = 1.5148).
Supplementary Figure 4 | (a) Log2 of the Euclidean distance (“perturbation”) of
IEC lineage marker gene expression of organoids treated with DMSO or inhibitors
for 96 h, including gene Defa22. Samples treated with HDAC inhibitors were
excluded from the analysis. Order is the same as in Figure 4A. (b) Scheme of flow
cytometry screen. Organoids were cultivated in 96-well plates, culture media was
changed daily. All pipetting steps were carried out with automated pipettes or
multichannel pipettes and samples were acquired on a flow cytometer with
automated plate handling. (c) Flow cytometry screening of organoids, treated with
DMSO or inhibitors for 96 h. Population frequencies in Cells, FSC_CD326hi and
FSC_CD24+ parent gate. Log2 fold change of gated populations normalized to
DMSO treatment. Median of 4wells/3 biol. replicates, samples with ≤4,000 cells
and populations containing ≤40 cells were excluded. Dot size corresponds to
absolute log2 fold change. Tree is based on Euclidean distance clustering of
populations in Cells parent gate. (d) Gene expression of organoids treated with
DMSO or GSK484 for 96 h, measured by qRT-PCR. GSK484 is an inhibitor of
arginine deiminase (PADI4). 4 biol. replicates, indicated by shape. Median
highlighted. (e) Gene expression of organoids treated with DMSO or SGC0946 for
96 h, measured by qRT-PCR. SGC0946 is an inhibitor of H3 lysine-79 specific
Histone-lysine N-methyltransferase (DOT1L). 4 biol. replicates, indicated by shape.
Median highlighted. (f–k) Gene expression of Alpi, Lgr5, Lyz1, Defa22, Muc2,
Agr2, Chga, Chgb, Cpe, Dclk1, Trpm5 Gfi1b in organoids treated with DMSO or
inhibitors for 96 h, measured by qRT-PCR. xfold change relative to DMSO-treated
organoids. 4 biol. replicates, indicated by shape. Median highlighted. Paired t-test
and false discovery rate (FDR) shown for p-values ≤0.1. (l) DCLK1+ cells per
crypt in colon of Villin-Cre+ Lsd1f/f (KO) mice with intestine-specific deletion of
Lsd1 and wild type (WT) littermates. Immunofluorescence staining of tissue
sections. Representative staining (left) and quantification in 5/3 mice, mean
highlighted. Unpaired t-test (right).
Supplementary Figure 5 | (a) Gene expression of organoids treated with (+)-JQ1
(left) or bromosporine (right) for 96 h, measured by qRT-PCR. xfold change relative
to DMSO-treated organoids. 4 biol. replicates, indicated by shape. Median
highlighted. (b) Organoids treated with (+)-JQ1 or bromosporine for 96 h.
Representative replicate from screen experiment. (c) BRD transcripts per million
(tpm) values in mRNA sequencing datasets of small intestinal crypts (3 mice) and
organoids (4 biol. replicates) from Zwiggelaar et al. (2020) (control groups from
E-MTAB-9077, E-MTAB-7862). (d) Gene expression of organoids treated with
PFI-1 for 96 h, measured by qRT-PCR. PFI-1 is an inhibitor of BRD2/BRD4. xfold
change relative to DMSO-treated organoids. 4 biol. replicates, indicated by shape.
Median highlighted.
Supplementary Figure 6 | (a) Gene expression of organoids treated with
SGC707 (left) or MS049 (right) for 96 h, measured by qRT-PCR. xfold change
relative to DMSO-treated organoids. 4 biol. replicates, indicated by shape. Median
highlighted. (b) Median organoid area and relative Lgr5 gene expression in DMSO
or MS023-treated organoids. 4 biol. replicates, indicated by shape. Median
highlighted. Paired t-test. (c) Frequency of Lgr5-EGFP stem cells in reporter
organoids treated with DMSO or MS023 for 96 h, measured by flow cytometry. 5
biol. replicates, indicated by shape. Mean highlighted (bottom). Paired t-test. (d)
Organoids treated with DMSO or MS023 for 96 h, and passaged to ENR for
additional 96 h. Images taken at 96 h timepoint and 24 and 96 h after passaging.
(e) mRNA sequencing of untreated vs. MS023 treated organoids. GSEA for Gene
Ontology biological process (GO:BP) terms. Normalized enrichment score (NES) is
indicated by color. Top 50 categories are shown. (f) mRNA sequencing of
untreated vs. MS023 treated organoids. GSEA for GO:BP terms “positive
regulation of cell development” (GO:0010720, NES = 1.6325), “lipid digestion”
(GO:0044241, NES = 1.9547), and “response to bacterium” (GO:0009617, NES
= 1.9257). (g) mRNA sequencing of untreated vs. MS023 treated organoids.
GSEA for GO:BP term “DNA repair” (GO:0006281, NES = −1.5531). (h) PRMT
transcripts per million (tpm) values in mRNA sequencing datasets of small intestinal
crypts (3 biol. replicates) and organoids (4 biol. replicates) from Zwiggelaar et al.
(2020) (control groups from E-MTAB-9077, E-MTAB-7862). (i) Box plots showing
tpm values from plate based scRNA sequencing from Haber et al. (GSE92332).
Tuft cell clusters have been merged into one group. (j) Apc-deficient adenomas
treated with DMSO, MS023, or TC-E5003 for 96 h. Representative well. (k)
Organoids treated with DMSO, MS023, or TC-E5003 for 96 h. Representative
replicate. (l) Viability of organoids treated with DMSO, MS023, or TC-E5003 for 96
h, measured by flow cytometry as frequency of Zombie Aqua-negative cells in
Singlet parent gate. 3 biol. replicates, indicated by shape.
Supplementary Table 1 | Inhibitors and concentrations used.
Supplementary Table 2 | qRT-PCR primers and probes used.
Supplementary Table 3 | Materials, reagents, and software used.
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